MedTrace Logo

Evaluation of the Efficacy of TOPIALYSE Baume Protect+ on Atopic Dermatis

NCT06108570 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-12-05

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and tolerability of a SVR care product.

As we know, atopic dermatitis is a vicious circle that must be broken, but certain aggravating factors are added to this circle. There is a lot of talk about pollution but, more recently, studies have been carried out on the worsening role of dust mites on atopic skin.

TOPIALYSE Baume Protect+ is a care product that is lipid-replenishing, repairing and protective: a triple reinforced action for 48 hours: anti-scratching, anti-irritation, and external anti-aggression. It is also intended for the whole family from birth for dry skin with an atopic tendency (with atopic eczema).

The main objective of this study is to evaluate the efficacy of the cosmetic product SVR TOPIALYSE Baume Protect+ versus Neutral Product on patients with mild atopic dermatitis, after 4 weeks of use with evaluation of the evolution mEASI (modified Eczema Area and Severity Index)

Conditions

Interventions

OTHER

Cosmetic Product TOPIALYSE Baume Protect+

One or two application.s of TOPIALYSE Baume Protect+ daily on one side for 28±3 days and the Neutral Product daily on the other side for 28±3 days. The side will be decided before by randomisation.

Sponsors & Collaborators

  • SVR Group

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Months
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-15
Primary Completion
2024-07-19
Completion
2024-08-22

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06108570 on ClinicalTrials.gov